Clinical Characteristics Associated with Bacterial Bloodstream Coinfection in COVID-19

Rebold, Nicholas; Alosaimy, Sara; Morrisette, Taylor; Holger, Dana; Lagnf, Abdalhamid M; Ansari, Iman; Belza, Ana Christine; Cheaney, Laura; Hussain, Huzaifa; Herbin, Shelbye R; Abdul‐Mutakabbir, Jacinda C.; Carron, Caitlin; Sandhu, Avnish; Chopra, Teena

doi:10.1007/s40121-022-00636-6

Cited by 5 publications

(10 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Two-hundred-forty-five studies were excluded for not reporting data on antibiotic use in COVID-19 patients. From the remaining 118 studies, 36 studies were included in this systematic review ( Figure 1 ) [ 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 ].…”

Section: Resultsmentioning

confidence: 99%

“…Of the 36 studies included in the systematic review, 32 studies were on the use of antibiotics in COVID-19 inpatients [ 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 ]; 4 reported on antibiotic use in COVID-19 outpatients [ 37 , 38 , 39 , 40 ].…”

Section: Resultsmentioning

confidence: 99%

“…Table 3 summarizes the findings of studies on bacterial infection and antibiotics use in hospitalized COVID-19 patients [ 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 31 , 32 , 33 , 34 , 35 , 36 ]. The majority of these studies report a low prevalence of bacterial coinfection in hospitalized COVID-19 patients.…”

Section: Resultsmentioning

confidence: 99%

“…Of note, the remaining studies reporting a higher prevalence of bacterial coinfection in hospitalized COVID-19 patients had small population sizes [ 8 , 9 , 10 , 11 , 12 , 14 , 31 , 32 , 34 , 35 , 36 ].…”

Section: Resultsmentioning

confidence: 99%

“…Rebold et al, performed a retrospective cohort study including 595 COVID-19 patients, reporting a 4.2% prevalence of bloodstream infection. In this study, 80% of the patients received empirical antibiotic treatment for a median of 10 days [ 35 ].…”

Section: Resultsmentioning

confidence: 99%

See 4 more Smart Citations

Antibiotics Use in COVID-19 Patients: A Systematic Literature Review

Granata

Schiavone

Pipitone

et al. 2022

JCM

View full text Add to dashboard Cite

The issue of bacterial infections in COVID-19 patients has received increasing attention among scientists. Antibiotics were widely prescribed during the early phase of the pandemic. We performed a literature review to assess the reasons, evidence and practices on the use of antibiotics in COVID-19 in- and outpatients. Published articles providing data on antibiotics use in COVID-19 patients were identified through computerized literature searches on the MEDLINE and SCOPUS databases. Searching the MEDLINE database, the following search terms were adopted: ((antibiotic) AND (COVID-19)). Searching the SCOPUS database, the following search terms were used: ((antibiotic treatment) AND (COVID-19)). The risk of bias in the included studies was not assessed. Both quantitative and qualitative information were summarized by means of textual descriptions. Five-hundred-ninety-three studies were identified, published from January 2020 to 30 October 2022. Thirty-six studies were included in this systematic review. Of the 36 included studies, 32 studies were on the use of antibiotics in COVID-19 inpatients and 4 on antibiotic use in COVID-19 outpatients. Apart from the studies identified and included in the review, the main recommendations on antibiotic treatment from 5 guidelines for the clinical management of COVID-19 were also summarized in a separate paragraph. Antibiotics should not be prescribed during COVID-19 unless there is a strong clinical suspicion of bacterial coinfection or superinfection.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 3 more Smart Citations

Antibiotics Use in COVID-19 Patients: A Systematic Literature Review

Granata

Schiavone

Pipitone

et al. 2022

JCM

View full text Add to dashboard Cite

show abstract

Association of COVID-19 coinfection with increased mortality among patients with Pseudomonas aeruginosa bloodstream infection in the Veterans Health Administration system

Hojat,

Wilson,

Perez

et al. 2023

ASHE

View full text Add to dashboard Cite

Objective: Pseudomonas aeruginosa bloodstream infection (PA-BSI) and COVID-19 are independently associated with high mortality. We sought to demonstrate the impact of COVID-19 coinfection on patients with PA-BSI. Design: Retrospective cohort study. Setting: Veterans Health Administration. Patients: Hospitalized patients with PA-BSI in pre-COVID-19 (January 2009 to December 2019) and COVID-19 (January 2020 to June 2022) periods. Patients in the COVID-19 period were further stratified by the presence or absence of concomitant COVID-19 infection. Methods: We characterized trends in resistance, treatment, and mortality over the study period. Multivariable logistic regression and modified Poisson analyses were used to determine the association between COVID-19 and mortality among patients with PA-BSI. Additional predictors included demographics, comorbidities, disease severity, antimicrobial susceptibility, and treatment. Results: A total of 6,714 patients with PA-BSI were identified. Throughout the study period, PA resistance rates decreased. Mortality decreased during the pre-COVID-19 period and increased during the COVID-19 period. Mortality was not significantly different between pre-COVID-19 (24.5%, 95% confidence interval [CI] 23.3–28.6) and COVID-19 period/COVID-negative (26.0%, 95% CI 23.5–28.6) patients, but it was significantly higher in COVID-19 period/COVID-positive patients (47.2%, 35.3–59.3). In the modified Poisson analysis, COVID-19 coinfection was associated with higher mortality (relative risk 1.44, 95% CI 1.01–2.06). Higher Charlson Comorbidity Index, higher modified Acute Physiology and Chronic Health Evaluation score, and no targeted PA-BSI treatment within 48 h were also predictors of higher mortality. Conclusions: Higher mortality was observed in patients with COVID-19 coinfection among patients with PA-BSI. Future studies should explore this relationship in other settings and investigate potential SARS-CoV-2 and PA synergy.

show abstract

The Evolving Challenge of Appropriate Antibiotics Use in Hospitalized COVID-19 Patients: A Systematic Literature Review

Granata,

Cicalini

2024

Antibiotics

View full text Add to dashboard Cite

The issue of bacterial infections in COVID-19 patients has received increasing attention. Scant data are available on the impact of bacterial superinfection and antibiotic administration on the outcome of hospitalized COVID-19 patients. We conducted a literature review from 1 January 2022 to 31 March 2024 to assess the current burden of bacterial infection and the evidence for antibiotic use in hospitalized COVID-19 patients. Published articles providing data on antibiotic use in COVID-19 patients were identified through computerized literature searches with the search terms [(antibiotic) AND (COVID-19)] or [(antibiotic treatment) AND (COVID-19)]. PubMed and SCOPUS databases were searched from 1 January 2022 to 31 March 2024. No attempt was made to obtain information about unpublished studies. English language restriction was applied. The quality of the included studies was evaluated by the tool recommended by the Joanna Briggs Institute. Both quantitative and qualitative information were summarized by means of textual descriptions. Five hundred fifty-one studies were identified, and twenty-nine studies were included in this systematic review. Of the 29 included studies, 18 studies were on the prevalence of bacterial infection and antibiotic use in hospitalized COVID-19 patients; 4 studies reported on the efficacy of early antibiotic use in COVID-19; 4 studies were on the use of sepsis biomarkers to improve antibiotic use; 3 studies were on the efficacy of antimicrobial stewardship programs and predictive models among COVID-19-hospitalized patients. The quality of included studies was high in 35% and medium in 62%. High rates of hospital-acquired infections were reported among COVID-19 patients, ranging between 7.5 and 37.7%. A high antibiotic resistance rate was reported among COVID-19 patients developing hospital-acquired infections, with a high in-hospital mortality rate. The studies evaluating multi-faceted antimicrobial stewardship interventions reported efficacy in decreasing antibiotic consumption and lower in-hospital mortality.

show abstract

Clinical Characteristics Associated with Bacterial Bloodstream Coinfection in COVID-19

Cited by 5 publications

References 44 publications

Antibiotics Use in COVID-19 Patients: A Systematic Literature Review

Antibiotics Use in COVID-19 Patients: A Systematic Literature Review

Association of COVID-19 coinfection with increased mortality among patients with Pseudomonas aeruginosa bloodstream infection in the Veterans Health Administration system

The Evolving Challenge of Appropriate Antibiotics Use in Hospitalized COVID-19 Patients: A Systematic Literature Review

Contact Info

Product

Resources

About